CA-125: a marker for persistent gestational trophoblastic disease?
The objective was to determine whether CA-125 levels have any clinical utility in gestational trophoblastic disease. Fifty-one patients with a pathologically confirmed diagnosis of complete hydatidiform mole had a CA-125 level obtained prior to suction molar evacuation. Data were analyzed using chi 2 and Mann-Whitney U test. CA-125 levels were twice as high in persistent gestational trophoblastic disease than those in complete hydatidiform molar patients (85.9 vs 48.3 U/ml; P = 0.004). CA-125 levels were independent of age, gravidity, weeks of amenorrhea, or presence of thecal-luteal cysts. CA-125 levels appear to be of value in predicting which molar patients will develop persistent disease.
Koonings
P P
PP
Division of Gynecologic Oncology, University of Southern California Medical Center, Los Angeles 90007.
Schalerth
J B
JB
D000328:Adult; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis*; D006063:Chorionic Gonadotropin / Q000032:analysis; D018997:Chorionic Gonadotropin, beta Subunit, Human; D005260:Female; D006801:Humans; D006828:Hydatidiform Mole / Q000276:immunology; D010446:Peptide Fragments / Q000032:analysis; D010865:Pilot Projects; D011247:Pregnancy; D011446:Prospective Studies; D014328:Trophoblastic Neoplasms / Q000276:immunology*; D014594:Uterine Neoplasms / Q000276:immunology*
D015295:Antigens, Tumor-Associated, Carbohydrate; D006063:Chorionic Gonadotropin; D018997:Chorionic Gonadotropin, beta Subunit, Human; D010446:Peptide Fragments